Roepstorff C - Search Results

1

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus.

Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H. Heise T, et al. Among authors: roepstorff c. Diabetes Ther. 2014 Jun;5(1):255-65. doi: 10.1007/s13300-014-0070-2. Epub 2014 Jun 3. Diabetes Ther. 2014. PMID: 24888255 Free PMC article.

2

Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.

Nosek L, Coester HV, Roepstorff C, Thomsen HF, Kristensen NR, Haahr H, Heise T. Nosek L, et al. Among authors: roepstorff c. Clin Drug Investig. 2014 Sep;34(9):673-9. doi: 10.1007/s40261-014-0218-x. Clin Drug Investig. 2014. PMID: 25124362 Free PMC article. Clinical Trial.

3

Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.

Heise T, Korsatko S, Nosek L, Coester HV, Deller S, Roepstorff C, Segel S, Kapur R, Haahr H, Hompesch M. Heise T, et al. Among authors: roepstorff c. J Diabetes. 2016 Jan;8(1):132-8. doi: 10.1111/1753-0407.12266. Epub 2015 Mar 24. J Diabetes. 2016. PMID: 25581159 Clinical Trial.

4

Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.

Hompesch M, Morrow L, Watkins E, Roepstorff C, Thomsen HF, Haahr H. Hompesch M, et al. Among authors: roepstorff c. Clin Ther. 2014 Apr 1;36(4):507-15. doi: 10.1016/j.clinthera.2013.12.014. Epub 2014 Feb 5. Clin Ther. 2014. PMID: 24508419 Clinical Trial.

5

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.

Koehler G, Heller S, Korsatko S, Roepstorff C, Rasmussen S, Haahr H, Pieber TR. Koehler G, et al. Among authors: roepstorff c. Diabetologia. 2014 Jan;57(1):40-9. doi: 10.1007/s00125-013-3056-0. Epub 2013 Sep 22. Diabetologia. 2014. PMID: 24057153 Free PMC article. Clinical Trial.

6

Insulin degludec: pharmacokinetics in patients with renal impairment.

Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Kiss I, et al. Among authors: roepstorff c. Clin Pharmacokinet. 2014 Feb;53(2):175-83. doi: 10.1007/s40262-013-0113-2. Clin Pharmacokinet. 2014. PMID: 24163264 Free PMC article. Clinical Trial.

7

Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.

Kupčová V, Arold G, Roepstorff C, Højbjerre M, Klim S, Haahr H. Kupčová V, et al. Among authors: roepstorff c. Clin Drug Investig. 2014 Feb;34(2):127-33. doi: 10.1007/s40261-013-0154-1. Clin Drug Investig. 2014. PMID: 24277680 Free PMC article. Clinical Trial.

8

Hormone-sensitive lipase serine phosphorylation and glycerol exchange across skeletal muscle in lean and obese subjects: effect of beta-adrenergic stimulation.

Jocken JW, Roepstorff C, Goossens GH, van der Baan P, van Baak M, Saris WH, Kiens B, Blaak EE. Jocken JW, et al. Among authors: roepstorff c. Diabetes. 2008 Jul;57(7):1834-41. doi: 10.2337/db07-0857. Epub 2008 Apr 8. Diabetes. 2008. PMID: 18398140 Free PMC article.

9

Intramuscular triacylglycerol in energy metabolism during exercise in humans.

Roepstorff C, Vistisen B, Kiens B. Roepstorff C, et al. Exerc Sport Sci Rev. 2005 Oct;33(4):182-8. doi: 10.1097/00003677-200510000-00006. Exerc Sport Sci Rev. 2005. PMID: 16239835 Review.

10

Studies of plasma membrane fatty acid-binding protein and other lipid-binding proteins in human skeletal muscle.

Roepstorff C, Helge JW, Vistisen B, Kiens B. Roepstorff C, et al. Proc Nutr Soc. 2004 May;63(2):239-44. doi: 10.1079/PNS2004332. Proc Nutr Soc. 2004. PMID: 15294037 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results